Trimetazidine-Teva, 20 mg 30 pcs

Pharmacological action – antianginal, antihypoxic, cytoprotective, metabolic.

Directly affects cardiomyocytes and neurons of the brain, optimizing their metabolism and functions. Cytoprotection is due to sufficient energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increase of aerobic glycolysis and blockade of fatty acid oxidation). Supports myocardial contractility, prevents intracellular depletion of ATP and phosphocreatinine. Under acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes and normalizes intracellular potassium content.

Limits intracellular acidosis and phosphate content caused by myocardial ischemia and reperfusion. Prevents damaging action of free radicals, maintains integrity of cell membranes, prevents activation of neutrophils in ischemic area, increases duration of electric potential, decreases release of creatine phosphokinase from cells and intensity of ischemic myocardial damage.

In angina pectoris it reduces the frequency of attacks (nitrates consumption decreases), after 2 weeks of treatment the tolerance to physical load increases, BP fluctuations decrease.

It improves hearing and results of vestibular tests in patients with ENT pathology, reduces dizziness and tinnitus. In case of vascular eye pathology it restores the functional activity of the retina.

It is completely and quickly absorbed from the gastrointestinal tract, the bioavailability is 90%. Tmax – 2 hours. Cmax after single oral administration of 20 mg trimetazidine is 55 ng/ml. Binding to plasma proteins is 16%. The volume of distribution is 4.8 l/kg. Easily passes through histohematic barriers. Almost half of the administered amount undergoes biotransformation. T1/2 is about 6 hours. 51% is excreted unchanged by the kidneys.

Indications

Active ingredient

Composition

1 film-coated tablet contains:

the active substance:

Trimetazidine dihydrochloride 20 mg;

auxiliary substances:

Microcrystalline cellulose 20.0 mg,

Mannitol 44.5 mg,

How to take, the dosage

The drug is taken with meals.

The drug is prescribed in a dose of 40-60 mg/day.

The frequency of administration is 2-3 times a day.

The duration of therapy is determined individually depending on the clinical situation.

Special Instructions

It is not used for relieving angina attacks!

The use of the drug does not affect the ability to drive and perform work requiring high-speed mental and physical reactions.

Contraindications

Side effects

Digestive system: rarely – nausea, vomiting.

Allergic reactions: skin rash, itching and other manifestations are possible.

Pregnancy use

Trimetazidine is contraindicated in pregnancy due to the lack of clinical data on the safety of its use.

Breastfeeding should be stopped if the drug has to be administered during lactation.

It is unknown whether trimetazidine is excreted with the breast milk.

The teratogenic effects of trimetazidine have not been established in experimental studies.

Similarities